Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule

Psoriasis is a complex chronic disease that can be challenging to manage, especially during pregnancy. The course of psoriasis can fluctuate throughout pregnancy as hormone levels change. In the only prospective study of pregnant patients with psoriasis, it was found that 55% of the patients reported improvement during pregnancy, 21% reported no change, and 23% reported worsening of psoriasis. However, postpartum, only 9% of patients reported improvement, 26% reported no change, and 65% reported worsening psoriasis. High levels of estrogen correlated with improvement in psoriasis, whereas progesterone levels did not correlate with psoriatic change (Murase et al., 2005).

It is now well known that Th1 and Th17 immunity plays a role in the current model of psoriasis pathogenesis. It has also been shown that pregnancy can be associated with diminished Th1 and Th17 mediated immunity, mainly due to the effects of increased estradiol. It is postulated that this increase promotes fetal survival by decreasing responses involved in rejection of the fetus (Sacks et al., 2001; Santner-Nanan et al., 2009). With all of these dynamics at play, it can be difficult for dermatologists to manage psoriasis in pregnant patients while protecting the fetus and mother.

When identifying medications and treatments to use in psoriasis patients during pregnancy, the old lettering categories of A, B, C, D, and X have served as surrogate markers of risk stratification. A review of treatment options for pregnant psoriasis patients found that most treatment options fall under category C, indicating that controlled studies in humans either have not been performed or are not available (Bae et al., 2012). Additionally, the 2012 National Psoriasis Foundation (NPF) consensus guidelines for treatment of all psoriasis patients propose first-line treatment with moisturizers and topical corticosteroids (preferably low to mid potency); second-line treatment with narrowband or broadband ultraviolet B; and third-line treatment with tumor necrosis factor inhibitors (adalimumab, etanercept, infliximab), cyclosporine, or systemic steroids (in second and third trimesters only). The NPF guidelines also state that systemic and biologic agents should be avoided in pregnancy and lactation unless there is a clear medical need (Chi et al., 2010). However, two major changes have occurred since the release of these guidelines that dermatologists should take into consideration. The introduction of a new pregnancy safety labeling system and the surge of newer biologic agents for the treatment of psoriasis into the marketplace will affect treatment options for pregnant patients.

Dermatologists should be knowledgeable about the recent Food and Drug Administration (FDA) changes in the way pregnancy safety is labeled on drugs. Effective June 30, 2015, the FDA released their Pregnancy and Lactation Labeling Rule (PLLR) which will be phased in over the next 3 years for existing drugs and required for all new drugs. The PLLR will introduce changes that aim to improve the communication and decision-making process between physicians and patients. The PLLR has several main changes, including the removal of pregnancy lettering categories; compression of population categories (e.g., pregnancy, labor and delivery, nursing mothers); and the implementation of a new risk narrative section. The PLLR will abolish lettering categories entirely and replace them with an individualized narrative summary of each drug which will include “risks of using a drug during pregnancy and lactation, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy and lactation” (FDA, 2014). It will also create new populations labels, with the former labels of “Pregnancy” and “Labor and Delivery” being combined and placed into a single category of “Pregnancy.” The former population label of “Nursing Mothers” will now be placed into the label of “Lactation.” Additionally, there will be an entirely new label of “Females and Males of Reproductive Potential,” which will discuss contraception recommendations, pregnancy testing, and information surrounding infertility associated with medication use.

The new changes introduced by the PLLR will aim to improve the former pregnancy lettering system, which has been criticized for being overly simplified, ambiguous, and incomplete (Addis et al., 2000; Boothby and Doering, 2000; Doering et al., 2002). This new narrative system will not only remove some of the prior ambiguity from the lettering system, but it will also present more information for physicians and patients to create a more individualized clinical decision. Additionally, this will help to reduce the “innocent until proven guilty” status that is placed on drugs, where untested drugs without any known harmful side effects are perceived to be safer (category B) than tested drugs with known side effects (category C). This narrative will provide more explicit detail on the sources of information and data pertaining to drugs. For example, the pharmaceutical drug pregnancy data information is obtained from animal studies in 92.9% of drugs, and only 5.2% obtained from human pregnancy data (Chambers, 2014; FDA, 1999; Mazer-Amirshahi et al., 2014). This kind of information will be made explicit in the new PLLR.

Since the last NPF guidelines on treatment of psoriasis in pregnancy were released in 2012, new biologic agents have come to market, with many more in the research pipeline. Currently, two new agents are on the market: an anti-Interleukin (IL)-17 agent, secukinumab, approved for moderate to severe plaque psoriasis in January 2015; and the small molecular inhibitor, apremilast, a phosphodiesterase...
4 inhibitor approved for moderate to severe plaque psoriasis in September 2014. Many other biologic agents and small molecule inhibitors are in the pipeline: anti–IL-17 agents such as ixekizumab, and brodalumab, and anti–IL-23 agents such as tildrakizumab and guselkumab (Mansouri and Goldenberg, 2015). Although phase 2 and 3 data from these drugs show very promising results for the treatment of psoriasis, additional considerations must be taken when treating pregnant psoriasis patients (Griffiths et al., 2015; Langley et al., 2015; Lebwohl et al., 2015). From these preliminary results, it appears that these drugs have similar safety profiles, with the most frequently reported adverse events being nasopharyngitis, upper respiratory infections, headache, and injection site reaction (Mansouri and Goldenberg, 2015). These adverse events are similar to those seen in older biologic agents such as adalimumab, etanercept, and infliximab (Mendes et al., 2014).

Few data are available evaluating the safety in pregnancy for adalimumab, etanercept, and infliximab, with an even further paucity of data regarding the newer biologic agents discussed. Several case series, case reports, and retrospective studies have concluded that adalimumab, etanercept, and infliximab have all been consistent with the old FDA categorization of pregnancy class B (Berthelot et al., 2009; Carter et al., 2006; Kane et al., 2009; Katz et al., 2004; Mahadevan et al., 2005; Mishkin et al., 2006; Murashima et al., 2009; Rump and Schönborn, 2010). This is all consistent with the 2012 NPF recommendations that these drugs should be regarded as third-line treatments for pregnant psoriasis patients (Bae et al., 2012). For these reasons and the changing PLLR classification system, we propose to update the recommendations to include the newest generation of biologic agents for psoriasis. Given that the advent of the newest generation of biologics is not mentioned in the 2012 guidelines, we endorse the extension of the same recommendations to all pregnant psoriasis patients for the anti–IL-17 agents (secukinumab, brodalumab, ixekizumab) and anti–IL-23 agents (BI 655066, guselkumab, tildrakizumab). These drugs, which are either currently on the market or in the pipeline, have demonstrated theoretical immunosuppressive risk and safety profiles similar to the previous generation of biologics and should be considered as such in pregnant psoriasis patients (Manalo et al., 2015; Mansouri and Goldenberg, 2015).

Although the new PLLR labeling system will provide additional narrative and data to the selection process of drugs in pregnancy, it will take time before adequate data are available to construct an acceptable narrative. Until all of the new data are in, it may be the best course of action to continue with first- and second-line treatment modalities for pregnant psoriasis patients and consider the new biologic agents as third-line treatment options. All physicians are encouraged to review the new labeling rules (Federal Register, 2014) in order to promote a smooth transition. For a more condensed version of the PLLR, please see U.S. Department of Health and Human Services (2014). Drug labels may be found at Dailymed (http://dailymed.nlm.nih.gov/dailymed/index.cfm).

Michael Abrouk, BS
Irvine School of Medicine, University of California, Irvine, CA
Corresponding Author
E-mail address: Michaelabrouk1@gmail.com

Kourosh Beroukhim, BS
David Geffen School of Medicine, University of California–Los Angeles, Los Angeles, CA

Mio Nakamura, MD
Department of Dermatology, Psoriasis, and Skin Treatment Center
University of California, San Francisco, CA

Tian Hao Zhu, BS
Keck School of Medicine, University of Southern California
Los Angeles, CA

Benjamin Farahnik, BS
College of Medicine, University of Vermont, Burlington, VT

Rasnik Singh, BS
David Geffen School of Medicine, University of California–Los Angeles, Los Angeles, CA

Merrick Brodsky, BS, BA
Irvine School of Medicine, University of California, Irvine, CA

Kristina Lee, BS
John Koo, MD
Tina Bhutani, MD
Department of Dermatology, Psoriasis, and Skin Treatment Center
University of California, San Francisco, CA

References
Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy. Drug Saf 2000;23:245–53. http://dx.doi.org/10.2165/00002018-200023030-00006.

Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012;67:459–77.

Berthelot JM, De Bandt M, Goupille P, Solau-Gervais E, Lionet F, Goeb V, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76:28–34.

Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother 2000;35:1485–9. http://dx.doi.org/10.1345/aph.1A034.

Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. Available from: http://www.jrheum.org/content/33/5/1014.short; 2006. 20 Oct 2015.

Chambers CD. Evaluating the impact of FDA’s pregnancy and lactation labeling rule. Dermatology News; 2014 [Available from: ]

Chi CC, Wang SH, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol 2010;62:694–705.

Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Available from: http://www.sciencedirect.com/science/article/pii/S0002937802001308; 2002. 20 Oct 2015.

Federal Register. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Available from: https://www.federalregister.gov/articles/2014/12/04/2014-28241/content-and-format-of-labeling-for-human-prescription-drug-and-biological-products-requirements-for; 2014. 20 Oct 2015.

Food and Drug Administration. Summary of comments from a public hearing and model pregnancy labeling based on recommendations. Available from: http://www.fda.gov/ucsf.idm.oclc.org/ohrms/dockets/ac/99/transcript/3516r1.doc; 1999.

Food and Drug Administration, Department of Health and Human Services. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. Fed Regist 2014;79: 72063–103.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015;386:541–51.

Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn’s disease before and after delivery. J Clin Gastroenterol 2009;43(7):761–6. http://dx.doi.org/10.1097/MCG.0b013e31817f9367.

Katz JA, Antolfi C, Kerian GF, Smith DE. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2583–92.

Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015;172:1371–83.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015;373: 1318–28.

Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission

"..."
in Crohn’s disease. Aliment Pharmacol Ther 2005;15:733–8. http://dx.doi.org/10.1111/j.1365-2036.2005.02405.x.

Manalo I, Gilbert K, Wu J. Preventing hepatitis B reactivation associated with immuno-suppressive drug treatments for psoriasis. J Am Acad Dermatol 2015;73:881–2.

Mansouri Y, Goldenberg G. New systemic therapies for psoriasis. Curr 2015;95:155–60.

Mazer-Amirshahi M, Samiie-Zafarghandy S, Gray G, van den Anker JN. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals. Am J Obstet Gynecol 2014;211:e1–11.

Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther 2014;39:307–13.

Mishkin DS, Deinse VW, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn’s disease in pregnancy. Inflamm Bowel Dis 2006;12:827–8. http://dx.doi.org/10.1097/00054725-200608000-00020.

Murai JI, Chatterjee, Garrett TJ, Cooper DM, Weinstein LD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005;141:601–6.

Murashiba A, Watanabe N, Ozawa N, Saito H. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 2009;68:1793–4.

Rump JA, Schönborn H. Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment [article in German]. Z Rheumatol 2010;69:903–9.

Sacks GP, Clover LM, Bainbridge DR, Redman CW, Sargent IL. Flow cytometric measurement of intracellular Th1 and Th2 cytokine production by human villous and extravillous cytotrophoblast. Placenta 2001;22:550–9.

Santner-Nanan B, Peek MJ, Khanam R, Richarts L, Zhu E, Fazekas de St Groth B, et al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J Immunol 2009;183:7023–30.

U.S. Department of Health and Human Services. Pregnancy, lactation, and reproductive potential: labeling for human prescription drug and biological products—content and format guidance for industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425398.pdf; 2014. 20 Oct 2015.